Boehringer Ingelheim Korea obtained additional indications of new oral anticoagulants (NOAC) and developed antidote
Boehringer Ingelheim Korea obtained additional indications of new oral anticoagulants (NOAC) 'Pradaxa (dabigatran)' including 'treatment and reducing recurrence risk of acute deep vein thrombosis (DVT) and pulmonary embolism (PE)'.
In addition to expanding indication, Boehringer Ingelheim was re...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
